Brussels, 28/06/2005 (Agence Europe) - In a 27 June press release, the European Agency for the Evaluation of Medicinal Products (EMEA) has announced the end of its examination of the Cox-2 inhibitors, which it began on 22 October 2004, a few weeks after the withdrawal of Merc&Co of its anti-inflammatory Vioxx. At the end of another medicines for human use committee meeting, EMEA confirms the suspension of another non-steroid anti-inflamatory belonging to this family: Bextra (valdecoxib),...